The COAPT Trial
The COAPT Trial is a new trial in the U.S. that will study an investigational device in patients who have functional mitral regurgitation and are considered extremely high-risk for mitral valve surgery.
Patients will be randomly assigned to a Device Group or Control Group. Both groups will receive the current recommended treatment, also known as the standard of care. For patients with mitral regurgitation who are considered extremely high-risk for mitral valve surgery, the standard of care may include one or more of these therapies:
- Implantation of a pacemaker, a device that delivers electrical impulses to help the heart beat normally
- Treatments for coronary artery disease
The COAPT Trial will study up to 420 patients at as many as 75 medical centers in the U.S.